India has built a strong position in the global pharmaceutical supply chain by providing high-quality generic medicines at affordable prices. The United States is its largest export market, where Indian companies supply medicines for diabetes, hypertension, cancer, high cholesterol, infectious diseases, and mental health conditions. Now, US President Donald Trump has announced a phased tariff plan on imported generic drugs.
Let us understand Trump’s new generic drug tariff plan in detail and see how it could affect Indian pharmaceutical companies, the American healthcare system, and investors.
What’s Happening?
According to Trump’s announcement, imported generic drugs in the United States will continue to attract a 0% tariff for two years, starting from 1 August 2026. From August 2028, the tariff will rise to 100% for one year, and from August 2029, it will increase further to 200%.
This effectively gives companies a two-year transition period to establish manufacturing facilities in the United States, including plants, equipment, and other infrastructure. Companies that do not begin production in the US within the stipulated timeframe could face significantly higher tariffs.
The proposed policy applies only to generic drugs. The existing policy for patented, branded, and innovative medicines will remain unchanged. According to the Trump administration, the objective is to bring generic drug manufacturing back to the United States, reduce dependence on foreign suppliers, and strengthen the country’s pharmaceutical security.
Why Is the Impact on India So Significant?
India is often referred to as the ‘pharmacy of the world’, and the United States is the largest export destination for Indian pharmaceutical companies. According to a report by the Global Trade Research Initiative (GTRI), India exported pharmaceutical products worth $9.7 billion to the US in 2025, accounting for 38% of its total pharmaceutical exports of $25.8 billion.
According to India’s Commerce Ministry, pharmaceutical exports to the US stood at $10.5 billion in FY 2024-25. Indian drugmakers export around $9-10 billion worth of generic medicines to the US every year.
Indian companies account for nearly 47% of all generic prescriptions filled in American pharmacies. On a volume basis, Indian generic drugs hold an estimated 40% market share. Since generic medicines account for more than 90% of all prescriptions in the US, this policy has significant implications not only for Indian exporters but also for American patients and the broader healthcare system.
Low Margins and Expensive US Manufacturing
The generic drug business operates on a high-volume, low-margin model. Compared to patented medicines, profitability is relatively limited. As a result, absorbing tariffs of 100% or 200% would be extremely difficult for most companies. Passing these additional costs on to consumers could make medicines significantly more expensive in the US.
The alternative is to manufacture locally in the United States. However, setting up new facilities would require substantial investment in land, manufacturing plants, equipment, regulatory approvals, and ongoing operating expenses. This would significantly alter the cost structure of Indian pharmaceutical companies.
Indian generic medicines helped the American healthcare system save an estimated $219 billion in 2022 alone. Over the past decade, these savings have totalled around $1.3 trillion. Therefore, any disruption in the supply of affordable Indian medicines could increase healthcare costs and affect the availability of essential drugs in the US.
What Does This Mean for Investors?
Following the announcement, investors have closely tracked US-focused Indian pharmaceutical companies such as Sun Pharma, Cipla, Dr Reddy’s Laboratories, Lupin, and Biocon, with several of these stocks witnessing declines. Since the 0% tariff will continue for the next two years, existing exports will not face any immediate additional duty. This provides companies with time to reassess and adjust their strategies.
However, investors should look beyond this temporary relief. The more important questions are which companies already have manufacturing facilities in the US, which are planning to expand local production, and which are best positioned to absorb higher costs.
For companies heavily dependent on generic drug exports, pressure on margins, pricing, and market share could increase after 2028. On the other hand, companies with strong balance sheets, diversified global operations, and an established manufacturing presence in the US may be better placed to navigate these challenges.
What’s Next?
The direct impact of this policy is expected to be felt from August 2028, but investment and manufacturing decisions are likely to begin much earlier. The next two years will not just provide temporary relief for Indian pharmaceutical companies; they will also be a crucial period for shaping their long-term strategy.
In February, India and the United States agreed to continue discussions on generic pharmaceuticals and pharmaceutical ingredients. As a result, it remains uncertain whether Indian companies will eventually receive exemptions, lower tariff rates, or a separate trade arrangement.
If tariffs of 100% and 200% are implemented without exemptions, Indian pharmaceutical companies may have to choose between expanding manufacturing in the US, increasing prices, or diversifying into new international markets. For investors, the long-term outlook will depend on the final policy framework, the progress of India-US trade negotiations, and how companies allocate capital to adapt to the changing environment.
Disclaimer: This article is for educational and informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. The companies mentioned are cited as examples within the context of market developments. Investors are advised to conduct their own due diligence and consult their financial advisor before making any investment decisions.
Investments in the securities market are subject to market risks. Read all related documents carefully before investing.
